{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:31:14Z","timestamp":1779312674433,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["beva.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Equine Veterinary Journal"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An extended\u2010release injectable omeprazole formulation (ERIO) has become a popular treatment for equine squamous gastric disease (ESGD) and equine glandular gastric disease (EGGD) where it is available; however, published data are limited and optimal treatment regimens have not been determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare effects of treatment on ESGD and EGGD when an ERIO formulation is administered at either 5\u2010 or 7\u2010day intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Retrospective clinical study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Case records and gastroscopy images of horses with ESGD or EGGD treated with ERIO were reviewed. Images were anonymised and graded by one researcher masked to treatment group. Treatment responses were compared between the two treatment schedules using univariable ordered logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty\u2010three horses were treated with ERIO at 5\u2010day intervals and 39 horses at 7\u2010day intervals. Signalment and presenting signs did not differ between groups. The proportions of horses with EGGD healing (to grade 0 or 1) in association with ERIO used at 5\u2010day intervals (93%) were higher than associated with treatment at 7\u2010day intervals (69%; odds ratio [OR]: 2.41, 95% CI: 1.23\u20134.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). For ESGD, there was no significant difference in the proportion of horses healing in association with treatment at 5\u2010day intervals (97%) compared with 7\u2010day intervals (82%; OR: 2.75, 95% CI: 0.91\u20138.31,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07). Four of 328 injections were associated with an injection\u2010site reaction (1%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main limitations<\/jats:title>\n                    <jats:p>Retrospective study design, lack of randomisation and limited case numbers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of ERIO at 5\u2010day intervals might be more appropriate than the 7\u2010day interval that is used currently.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/evj.13938","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T21:34:10Z","timestamp":1680039250000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Five\u2010 versus seven\u2010day dosing intervals of extended\u2010release injectable omeprazole in the treatment of equine squamous and glandular gastric disease"],"prefix":"10.1111","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0556-4406","authenticated-orcid":false,"given":"Tania","family":"Sundra","sequence":"first","affiliation":[{"name":"Avon Ridge Equine Veterinary Services  Brigadoon Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Kelty","sequence":"additional","affiliation":[{"name":"School of Population and Global Health The University of Western Australia  Crawley Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6943-6425","authenticated-orcid":false,"given":"David","family":"Rendle","sequence":"additional","affiliation":[{"name":"EMT Consulting  Tiverton Devon UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.13578"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.12968\/ukve.2018.2.S1.3"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-3306.1999.tb05176.x"},{"issue":"7","key":"e_1_2_13_5_1","first-page":"581","article-title":"Efficacy of a paste formulation of omeprazole for the treatment of naturally occurring gastric ulcers in training standardbred racehorses in Canada","volume":"44","author":"Doucet MY","year":"2003","journal-title":"Can Vet J"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2005.227.1636"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-3306.1997.tb03153.x"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.12287"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.12191"},{"key":"e_1_2_13_10_1","unstructured":"RendleD HallowellG.Treatment of equine glandular gastric disease in elite endurance horses with oral and long\u2010acting injectable omeprazole: a randomised blinded clinical trial. In: Proceedings of the European College of Equine Internal Medicine Congress Valencia Spain.2019."},{"key":"e_1_2_13_11_1","unstructured":"PicklesKJ BlackK BruntO CraneM.Retrospective study of misoprostol treatment of equine glandular gastric disease. In: Proceedings of the European College of Equine Internal Medicine Congress; Online 2020."},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.13087"},{"key":"e_1_2_13_13_1","unstructured":"KranenburgLC ScheepbouwerJHT van denBoomR.Retrospective study of combined sucralfate and omeprazole therapy compared with omeprazole monotherapy for equine glandular disease. In: Proceedings of the European College of Equine Internal Medicine Congress; Online 2020."},{"key":"e_1_2_13_14_1","unstructured":"HepburnRJ ProudmanCJ.Treatment of ulceration of the gastric glandular mucosa: retrospective evaluation of omeprazole and sucralfate combination therapy in 204 sport and leisure horses (Abstract). In: Proceedings of the International Colic Symposium. Dublin Ireland;2014."},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/vms3.728"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.12688"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/vms3.220"},{"key":"e_1_2_13_18_1","unstructured":"RendleD.Treatment of equine squamous gastric disease in elite endurance horses with oral and long\u2010acting injectable omeprazole: a randomised blinded clinical trial. In: Proceedings of the European College of Equine Internal Medicine Congress. Valencia Spain;2019."},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-3292.1999.tb00961.x"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.12486_18"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000200917"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/eve.13546"},{"key":"e_1_2_13_23_1","unstructured":"BartonA MerleR GehlenH.Efficacy of two oral omeprazole formulations for the therapy of equine gastric ulcer disease. In: Proceedings of the European College of Equine Internal Medicine Congress; Online 2021."},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/eve.12894"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12210"}],"container-title":["Equine Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/beva.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/evj.13938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:37:58Z","timestamp":1762083478000},"score":1,"resource":{"primary":{"URL":"https:\/\/beva.onlinelibrary.wiley.com\/doi\/10.1111\/evj.13938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/evj.13938"],"URL":"https:\/\/doi.org\/10.1111\/evj.13938","archive":["Portico"],"relation":{},"ISSN":["0425-1644","2042-3306"],"issn-type":[{"value":"0425-1644","type":"print"},{"value":"2042-3306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"2022-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}